Related Experiment Video
Updated: Feb 7, 2026

Analysis of the Ambient Particulate Matter-induced Chromosomal Aberrations Using an In Vitro System
Published on: December 21, 2016
Simvastatin attenuates the aberrant expression of angiogenic factors induced by glucose variability
Marzena Dworacka1, Saule Iskakova2, Anna Wesołowska1
1Department of Pharmacology, Poznan University of Medical Sciences, Rokietnicka 5d, 60-805 Poznań, Poland.
Insights
Simvastatin treatment in diabetic rats with glucose variability reduced glucose fluctuations and altered angiogenic factors in the cardiovascular system, potentially mitigating atherosclerosis risk.
Area of Science:
- Cardiovascular Science
- Endocrinology
- Pharmacology
Background:
- Fluctuant hyperglycemia increases cardiovascular complication risk in diabetes.
- Statins are used for cardiovascular prevention in diabetes, but their effect on glucose variability-induced angiogenesis is unclear.
- Aberrant angiogenesis is a key factor in atherosclerosis development.
Purpose of the Study:
- To investigate the effect of simvastatin on glucose variability and associated angiogenic factors in a type 2 diabetes rat model.
- To determine if simvastatin can prevent aberrant angiogenesis induced by glycemic variability.
Main Methods:
- A type 2 diabetes rat model with daily glucose excursions was established.
- Rats were treated with simvastatin (20 mg/kg) or placebo for 8 weeks.
- Measurements included daily glucose fluctuations, angiogenic factors (VEGF, TGF-beta), and endothelial cells.
Main Results:
- Simvastatin reduced circulating VEGF and TGF-beta expression in the myocardium, and VEGFR-2 in the aorta, which were elevated by glucose excursions.
- Simvastatin increased myocardial and aortic VEGF and VEGFR-1 expression, which were attenuated by glucose fluctuations.
- Simvastatin treatment lowered circulating endothelial cells and increased progenitor endothelial cells in diabetic rats with glycemic variability.
Conclusions:
- Simvastatin effectively reduces glucose variability in a rat model of type 2 diabetes.
- Simvastatin mitigates glucose variability-induced changes in angiogenic factor expression within the cardiovascular system.
- These findings suggest simvastatin may offer a protective effect against atherosclerosis development in diabetic patients with glycemic variability.
Aim:
Over the last few years, studies have indicated that fluctuant hyperglycemia is very likely to increase the risk of cardiovascular complications of diabetes. Statins are widely used in diabetes for the prevention of cardiovascular complications, but it is still not clear whether simvastatin could also prevent glycaemic variability - induced aberrant angiogenesis which plays a significant role in the development of atherosclerosis.
Methods:
Wistar rats were divided into four groups: (1) simvastatin-treated (20 mg/kg for 8 consecutive weeks) type 2 diabetes rat model with daily glucose excursions, (2) placebo-treated type 2 diabetes rat model with daily glucose excursions, (3) placebo-treated stable well-controlled type 2 diabetes rat model and (4) placebo-treated non-diabetic rats. Daily glucose fluctuations and several angiogenic factors: cVEGF, mRNA VEGF, VEGF-R1, VEGF-R2, TGF-beta expression, circulating endothelial and progenitor endothelial cells were measured in all groups.
Results:
Simvastatin decreased several factors enhanced by glucose excursions: circulating VEGF, mRNA TGF-beta expression in the myocardium and mRNA VEGFR-2 expression in the aorta. Simvastatin increased some factors attenuated by glucose fluctuations: mRNA VEGF expression and mRNA VEGFR-1 expression in the myocardium and in the aorta. In the simvastatin-treated group with glycaemic variability, the percentage of circulating endothelial cells was lower and the percentage of progenitor endothelial cells in peripheral blood was higher than in the placebo-treated rats with glucose-fluctuations.
Conclusions:
Simvastatin used in the rat model of type 2 diabetes with glucose variability reduces glucose variability and limits glucose fluctuations-induced changes in the expression of angiogenic factors in the cardiovascular system.
More Related Videos
06:28A Simple Flow Cytometric Method to Measure Glucose Uptake and Glucose Transporter Expression for Monocyte Subpopulations in Whole Blood
Published on: August 12, 2016
08:51Applying an Inducible Expression System to Study Interference of Bacterial Virulence Factors with Intracellular Signaling
Published on: June 25, 2015
Related Concept Videos
Transcription Attenuation in Prokaryotes
There are several different mechanisms used to attenuate transcription. In ribosome mediated...
Transcription Factors
Cell Specific Gene Expression
Glucose Homeostasis: Regulation of Blood Glucose
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
Variability: Analysis
The range is a simple measure of variability, indicating the difference between the highest and...
Random Variables
Uppercase letters such as X or Y denote a random variable. Lowercase letters like x or y denote the value of a random variable. If X is a random variable, then X is written in words, and x is given as a number.
For example, let X = the...